Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Brigatinib
Brand Name Alunbrig®
Payment Category Medicare Part D
Year Introduced 2017
Type of Drug Kinase inhibitor
Manufacturer Takeda
Medical Affairs Questions (date verified) 877.825.3327
Coverage & Reimbursement Questions 844.217.6468

FDA-Approved Indication(s)

  • Indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer, as detected by an FDA-approved test. (5/26/20)

Approved Indication(s) with Orphan Drug Status Treatment of ALK+ non-small cell lung cancer
ICD-10 Code(s) for Labeled Indication(s) Malignant neoplasm of bronchus and lung [C34.xx]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US